Skip to content
LUNGevity Foundation· @LUNGevity · X·· 2026-04-20Score60

KRAS

Reading

KRAS / RAS targeting: from platform to Phase 3

First-generation G12C drugs (sotorasib, adagrasib) bind KRAS in the off state. After treatment, RTK feedback reloads KRAS into the on state.

Body

@DocSacher

@pmcancercentre
answers a key question - "Does the world need another KRAS G12C OFF inhibitor?" #AACR26
Key benchmarks for any new G12Ci:
Primary resistance & ORR
Durability of response
Toxicity profile (autoimmune hepatotoxicity!)
Activity in hard-to-treat

Heat 6 · 4 likes · 0 replies · 2 reposts

Conference abstracts
CT129matched by 摘要号 CT129
Preliminary results from a Phase 1a/b dose-escalation and expansion trial of the pan-RAF-MEK molecular glue NST-628 in patients (pts) with advanced or refractory RAF, KRAS, and NRAS-mutant solid tumors

Ahmad A. Tarhini, Monica Chen, Jia Liu, Varun Monga, Victoria Atkinson, Sarina A. Piha-Paul, Bartosz Chmielowski, Benjamin Herzberg, Charlotte Lemech, Prachi Bhave, Ganessan Kichenadasse, Gerald Falchook, Janice Mehnert, Andrae Vandross, Mohamad Salkeni, Meredith McKean, David Wages, Ann Marie Kennedy, Meagan B. Ryan, John Clark, Abdulaziz Nanah, Michael J. Fossler, Philip Komarnitsky, Igor Puzanov

Read the abstract →
CT303NCT05410145matched by 药名 cetuximab
Safety and efficacy of Elisrasib (D3S-001), a next generation GDP-bound KRAS G12C inhibitor, as monotherapy or combination therapy with cetuximab in previously treated metastatic CRC and PDAC: Results from a phase 1/2 study

Kanwal Pratap Raghav, Jun Zhang, Myung-Ah Lee, Jingdong Zhang, John Park, Yanqiao Zhang, Susana Rosello Keranen, Byoung Chul Cho, Herbert Ho Fung Loong, Cheng Chen, Huan Li, Shaonan Wang, Yandong Shen, Zifei Fan, Qian Chen, Hui Wang, Jing Zhang, George Zhi Jian Chen, Jayesh Desai, Antoine Hollebecque

Read the abstract →

Source: LUNGevity Foundation · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org